Palliative Care Considered Beneficial, Though Infrequently Used in Lung Cancer
A team of international investigators deployed a survey to understand the needs of patients with EGFR-positive lung cancer community.
Lung Cancer
Durvalumab After Chemoradiotherapy Cost-Effective for NSCLC
The addition of durvalumab after chemoradiotherapy for treatment of stage III NSCLC was cost-effective compared with chemoradiotherapy alone.
Carboplatin Plus Nab-Paclitaxel and RT Promising for Advanced NSCLC in the Elderly
A team of investigators sought to determine outcomes from combination low-dose carboplatin plus nab-paclitaxel with concurrent radiotherapy among elderly patients with advanced non-small cell lung cancer.
Keytruda Indication for Metastatic Small Cell Lung Cancer Withdrawn
Continued approval of the indication was contingent upon establishing the superiority of Keytruda as determined by overall survival.
Cosela Now Available to Reduce Chemotherapy-Induced Bone Marrow Suppression in ES-SCLC
The approval was based on data from 3 randomized, placebo-controlled trials that included 245 adults with ES-SCLC.
FDA-Approved Non-Small Cell Lung Cancer (NSCLC) Treatments
Chemotherapeutic and biologic agents for the treatment of non-small cell lung cancer (NSCLC).
Patient-Reported Outcomes With Lorlatinib in NSCLC
Although patient-reported outcomes measures were similar with lorlatinib and crizotinib in non-small cell lung cancer, more patients reported improvement in symptoms with lorlatinib.
Delay in Initiating RT After Chemotherapy in Locally Advanced NSCLC May Shorten DFS
A team of investigators sought to determine whether the timing of radiotherapy after induction chemotherapy affected survival in patients with locally advanced non-small cell lung cancer.
Prolonged Survival With Durvalumab in Stage III NSCLC With High PD-L1 Expression
Investigators conducted a retrospective chart review that assessed data from patients with unresectable, stage III NSCLC to assess real-world survival outcomes associated with durvalumab.
ECOG Performance Status Outcomes With Pembrolizumab in NSCLC
A single-center cohort study assessed progression-free survival and overall survival in patients with advanced NSCLC who received palliative pembrolizumab therapy.
-
Loading...
-
Loading...
Next post in Lung Cancer
